Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, review the rapidly evolving frontline treatment landscape for EGFR-mutated advanced non–small cell lung cancer (NSCLC). Vokes highlights the shift from EGFR TKI monotherapy toward combination approaches designed to deepen and prolong responses. Devarakonda discusses how recent clinical trial data are redefining benchmarks for progression-free survival and influencing first-line standards of care.